Urgent.News

What's breaking now, across thousands of outlets.

Tech

'Nobody Wants This' season 3 review: Did someone accidentally hit the romance fast-forward button?

Our ‘Nobody Wants This’ season 3 review finds it as charming and funny as ever, but Joanne and Noah’s romance moves at warp speed, rushing through major milestones along the way.

'Nobody Wants This' season 3 review: Did someone accidentally hit the romance fast-forward button?

Netflix's "Nobody Wants This" season 3 finally gives its central couple, Joanne and Noah, the chance to enjoy being a couple. They move in together, plan a future, and Joanne starts converting to Judaism. These developments are exciting, but the fast pace of the season leaves little room to savor the milestones. While Kristen Bell and Adam Brody's chemistry shines through, the quick progression of their relationship feels rushed.

Sarah Silverman and Andrew Rannells bring fresh energy to the show as Rabbi Eden and Sebastien, a fellow student. However, the increased plot complexity can feel overwhelming, with multiple romantic storylines competing for attention. The finale sees Joanne and Noah eloping, suggesting a possible conclusion to their story. Despite these pacing issues, the season remains a charming rom-com, with the cast continuing to deliver appealing performances.

Written by urgent.news from Tom's Guide's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at tomsguide.com →

More in Tech

Celltrion Secures Global Rights to Kaigene’s KG013, Expanding Autoimmune Drug Pipeline

Celltrion is strengthening its next-generation drug development portfolio by securing global rights to KG013, an investigational antibody therapy for autoimmune diseases developed by U.S.-based…

  • Celltrion secures global rights to KG013 antibody therapy for $580.5 million.
  • KG013 targets APRIL protein to treat IgAN and potentially other immune conditions.
  • Partnership expands Celltrion's autoimmune drug pipeline with two additional Kaigene therapies.

More from Thursday 22 October →